 Shares of Sarepta Therapeutics Inc. gained 11.3 in trading on Tuesday after the company shared positive data from a mid-stage, open-label clinical trial for its experimental Duchenne muscular dystrophy treatment. The data comes from the first 11 enrolled participants in a study of 20 participants who are between the ages of 4 and 7 years old. 